Workflow
PTC(PTC)
icon
Search documents
PTC Therapeutics to Participate at Upcoming Investor Conference
prnewswire.com· 2024-05-29 12:00
WARREN, N.J., May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th Annual Growth Stock Conference Tuesday, June 4, at 9:00 am ET / 8:00 am CT The presentation will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It ...
PTC Therapeutics Announces Validation of Sepiapterin European MAA
prnewswire.com· 2024-05-28 12:30
- Review of European marketing application for PKU now initiated - WARREN, N.J., May 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA. "The validation of the MAA is an important step towards making sepiapterin available to children and adults affected by PKU in Europe," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "The European submission is the first of several g ...
PTC Stock Surges 41% in a Year: Will the Rally Continue?
zacks.com· 2024-05-23 14:51
PTC Inc (PTC) is continuing its upward trajectory, with a gain of 41% in the past year compared with the S&P 500 composite and sub-industry's growth of 29.2% and 35.7%, respectively. PTC is a software provider offering a comprehensive portfolio of software including computer-aided design (CAD) and product lifecycle management (PLM) solutions. The company's software can be delivered on- premises, in the cloud or in a hybrid model. Solid financial performance has been driving a good run on the trading front. ...
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
prnewswire.com· 2024-05-20 11:00
WARREN, N.J., May 20, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation. As a result, Translarna remains on the market and available for patients in Europe consistent with its current marketing authorization. The EC has asked the ...
It's Time to Buy This Hot Technology Stock on a Dip
The Motley Fool· 2024-05-11 15:14
The industrial software company's recent results gave investors confidence in it hitting its full-year guidance.Industrial software company PTC's (PTC) stock has dipped recently, and investors, initially at least, reacted negatively to the company's fiscal second-quarter earnings, which it released at the start of May. Is the trend likely to continue, or is now an excellent time to pick up stock in an exciting growth company?PTC's recent big newsInvestors usually pencil in assumptions for medium-term growth ...
PTC(PTC) - 2024 Q2 - Quarterly Report
2024-05-03 20:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_ to_ Commission File Number: 0-18059 PTC Inc. (Exact name of registrant as specified in its charter) Massachusetts 04-2866152 (State or other jurisdiction of incorporati ...
PTC's Q2 Earnings Beat Estimates, Revenues Increase Y/Y
Zacks Investment Research· 2024-05-02 14:11
PTC Inc. (PTC) reported second-quarter fiscal 2024 non-GAAP earnings per share (EPS) of $1.46, up 26% on a year-over-year basis. Also, the figure surpassed the Zacks Consensus Estimate by 18.7%.Revenues came in at $603 million, up 11% year over year (up 11% at constant currency or cc). The top line beat the Zacks Consensus Estimate by 4.8%.The year-over-year improvement in the top line was driven by steady demand for its computer-aided design (CAD) and product lifecycle management (PLM).Top Line in DetailRe ...
PTC(PTC) - 2024 Q2 - Earnings Call Transcript
2024-05-02 10:01
Matt Shimao - Head of Investor Relations Neil Barua - Chief Executive Officer Kristian Talvitie - Chief Financial Officer Operator Matt Shimao Today's conference call is being broadcast live through an audio webcast and a replay of the call will be available later today at www.ptc.com. With that, I'd like to turn the call over to PTC's Chief Executive Officer, Neil Barua. I'm proud of what the PTC team accomplished during our second fiscal quarter. We again delivered solid results, which Kristian will take ...
PTC(PTC) - 2024 Q2 - Earnings Call Presentation
2024-05-02 08:00
CAD SaaS Converting our installed base Growth primarily driven by Windchill Americas Europe APAC | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|---------------|---------------|-------|-------|-------|-------------|-----------|-------|-------|------------|-------------| | $929 | $929 | $1,029 \n+11% | $1,029 \n+11% | $667 | $654 | | $758 \n+14% | $744 +14% | $286 | $267 | $302 \n+6% | $302 \n+13% | | | Q2'23 | | Q2'24 | | Q2'23 | | Q2'24 | | | Q2'23 | Q2'24 | ...
Compared to Estimates, PTC Inc. (PTC) Q2 Earnings: A Look at Key Metrics
Zacks Investment Research· 2024-05-01 22:31
PTC Inc. (PTC) reported $603.07 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 11.2%. EPS of $1.46 for the same period compares to $1.16 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $575.53 million, representing a surprise of +4.79%. The company delivered an EPS surprise of +18.70%, with the consensus EPS estimate being $1.23.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...